Vermillion's Q2 Revenues Flat at $323,000

NEW YORK (Genomeweb News) – Vermillion reported after the close of the market Wednesday that its second quarter revenues were essentially flat year over year at $323,000 versus $321,000 in Q2 2012.

The company posted product revenue of $210,000, up 1 percent from $208,000 year over year. That revenue was based on 4,184 OVA1 ovarian cancer tests performed in Q2 2013 versus 4,150 tests performed in the year-ago period.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.

The Union of Concerned Scientists surveyed US government scientists about Trump Administration policies and more, Science reports.

National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.

In PNAS this week: history and genetic diversity of the scarlet macaw, approach for predicting human flu virus evolution, and more.

Aug
23
Sponsored by
Tecan

This webinar will discuss an automated, high-throughput method of generating high-quality antigens and antibodies.